ClinicalTrials.gg
CompletedNCT07941882Updated Nov 17, 2026

Analysis of Music in Ketamine Infusion Therapy

An observational study in Treatment Resistant Depression (TRD), sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Utah · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Enrollment
14th of 23
50 · median 66
Started
2025
with 11 others
Observational
23 of 205
6 open now
Registered
182nd of 205
by date

Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 14th largest by enrollment of the 23 observational ones that give a count, is one of 12 that started in 2025, is one of 23 observational ones, and was the 182nd registered.

Depressive Disorder, Treatment-Resistant

449 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

This study will be conducted at HMHI's treatment resisted mood disorder clinic (TRMD) and will collect data from patient's receiving ketamine infusion treatments (KIT) for TRD. Data will be collected for two separate cohorts, representing two different stages in treatment, acute series (initial 6-12 session) and maintenance (will collect data from up to 6 maintenance sessions).

The goal of the study will be to explore to role of music in this treatment modality and how personal choice and properties of music played during the treatments affects experiential and clinical outcomes.

03

Conditions studied

  • Treatment Resistant Depression (TRD)

Keywords

  • TRD
  • ketamine
  • music
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient age 18 or older who are getting KIT, or who plan to start KIT at the HMHI TRMD clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults at least age 18 years or more(no upper limit)
  2. Intention to start or referral for ketamine infusion therapy, after independent clinical evaluation, at the Treatment Resistant Mood Disorders Clinic at the Huntsman Mental Health Institute

Exclusion criteria

Exclusion Criteria:

  1. Discontinuation of Ketamine infusions, for any reason, as determined by the clinicians at the Treatment Resistant Mood Disorders Clinic at the Huntsman Mental Health Institute
  2. Unable to complete study assessments or comply with study protocol
  3. Non-English speaking patients - Given the limited scope and financial support (pilot project funded via research track) of the project we are concerned that it would mostly be a financial and logistical burden to the study. The clinic we will be recruiting from does not have a substantial non-English speaking population, and we are worried that recruiting them would not substantially contribute to the diversity of our sample. We are concerned that it will mostly just increase financial burden (e.g. hiring translations services for recruitment meetings and potential prolongation for such meetings), as well as increase the logistical/analytical burden (e.g. potential longer meeting introducing confounding factors that can't be accounted for since sample size will be to small to do reliable subgroup analysis, confounding factors relating to presence of lyric and they intelligibility, etc.). We believe this will make our study more scientifically reliable and thus more likely to contribute to improvement of clinical practices.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Clinic's playlist

    Patients that listen to the music being played in the clinic on speakers

  • Personal playlist

    Patient that listen to their personally chosen playlist

  • No music

    Patient who do not want to listen to music during their treatment

06

What researchers measure

Primary outcomes

  1. Quick Inventory of Depressive Symptoms

    QIDS; this 16-item scale has scores ranging from 0 to 27. Higher scores imply worse depression. It is interpreted as follows: * 0 - 5: Normal / No Depression (or minimal symptoms) * 6 - 10: Mild Depression * 11 - 15: Moderate Depression * 16 - 20: Severe Depression * 21 - 27: Very Severe Depression

    Time frame: Baseline and prior to each infusion (up to two infusions per week), for up to 12 infusion sessions during the acute treatment phase, and for up to six weekly maintenance infusions

Secondary outcomes

  1. CEQ-7

    Challenging Experience Questionnaire 7-Item. Scores range from 0 to 35. Higher scores indicate a more challenging experience (typically associated with psychedelic or dissociative compound administration)

    Time frame: within 24 hours of each infusion for up to 12 twice-weekly infusions during the acute phase and up to 6 weekly maintenance infusions

  2. MEQ-4

    4-item Mystical Experience Questionnaire. Scores range from 0 to 20. Higher scores indicate a more mystical or more intensely spiritual experience.

    Time frame: up to 12 months

07

Study locations

1 site
  • University of Utah, Huntsman Mental health Institute
    Salt Lake City, Utah 84108, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jul 2026, 11 months.

Of 33 observational studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 65. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Nov 17, 2026
StartActual
Jul 21, 2025
Primary completionActual
Jul 1, 2026
CompletionActual
Jul 1, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07941882
Lead sponsor
University of Utah
Responsible party
Brent Michael Kious, MD, PhD (Associate Professor, University of Utah) — Principal investigator
First posted
Nov 17, 2026
Start date
Jul 21, 2025
Primary completion
Jul 1, 2026
Completion
Jul 1, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion